JW To Progress Dendritic Cell Therapeutics After Fund Raising
This article was originally published in PharmAsia News
Executive Summary
South Korea's JW Group is accelerating efforts to develop cancer immune cell therapies by raising a total of KRW50bn ($42.9m), with the funds to be used for its novel drug development arm JW CreaGene, which has a number of innovative dendritic cell-based candidates in the pipeline.